The objective of the current program of research will be to test whether intranasal ketamine
treatment is more effective than placebo in reducing suicidal ideation in suicidal patients
presenting for acute treatment in emergency department settings. Secondary objectives will
test the effect of genotypic differences in the mu opioid receptor on efficacy of ketamine
and the correlation of speech patterns and facial movement patterns with subjective
reductions in suicidal ideation after ketamine treatment.